Fan F(X), Zhao W, Liu J, He A, Chen Y, Cao X

[1] Fan F(X), Zhao W, Liu J, He A, Chen Y, Cao X, Yang N, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol 35, 2017 (suppl; abstr LBA3001)
[2] The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute http://seer.cancer.gov/statfacts/html/mulmy.html Last accessed June 4, 2017.
[3] Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.
[4] World Cancer Report 2014. International Agency for Research on Cancer; World Health Organization; 1 edition (April 1, 2014) ISBN: 9283204298; Chapter 2.3 and 2.6
[5] Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, Vollset SE, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.
[6] Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.